Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Gross Margin (2018 - 2025)

Dna X filings provide 8 years of Gross Margin readings, the most recent being 11.2% for Q3 2025.

  • On a quarterly basis, Gross Margin fell 1697.0% to 11.2% in Q3 2025 year-over-year; TTM through Sep 2025 was 20.94%, a 1007.0% decrease, with the full-year FY2024 number at 19.48%, down 116.0% from a year prior.
  • Gross Margin hit 11.2% in Q3 2025 for Dna X, up from 7.55% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 49.97% in Q1 2025 to a low of 3.06% in Q4 2021.
  • Median Gross Margin over the past 5 years was 16.49% (2023), compared with a mean of 19.09%.
  • Biggest five-year swings in Gross Margin: surged 2182bps in 2023 and later crashed -4053bps in 2024.
  • Dna X's Gross Margin stood at 3.06% in 2021, then skyrocketed by 633bps to 16.3% in 2022, then soared by 134bps to 38.12% in 2023, then plummeted by -106bps to 2.41% in 2024, then soared by 565bps to 11.2% in 2025.
  • The last three reported values for Gross Margin were 11.2% (Q3 2025), 7.55% (Q2 2025), and 49.97% (Q1 2025) per Business Quant data.